TP-6379

TP-6379 is an investigational **orally available small-molecule inhibitor** of **transforming growth factor beta receptor 1** designed to block TGF-β/SMAD signaling. The program has been attributed to **Sumitomo Pharma Oncology** and is described as a preclinical oncology asset with activity reported in tumor models including **ovarian cancer** and **triple-negative breast cancer**, both as monotherapy and in combination settings such as paclitaxel or immunotherapy. Its intended therapeutic rationale is to counter TGF-β-driven tumor microenvironment remodeling, immune evasion, epithelial-mesenchymal transition, and metastatic progression.